While the prevalence of rare disorders in New Zealand might be up for debate, the impact of a rare disorder diagnosis is not - it's life-changing. However, access to publicly funded medication is limited, with patients facing multiple barriers to treatment.
A Trans-Tasman collaboration is conducting clinical trials across both Australia and New Zealand in a bid to widen the access to investigational medication. Dr Richard Stubbs, the Chief Medical Officer at Momentum Clinical Research, speaks to Jesse.
Photo: AFP / Tek Image/Science Photo Library
